The popularity of direct anterior approach THA is driving new product introductions.

With the exploding growth of enabling technology, much of the focus on implant solutions in recent years has been on knee replacement systems compatible with enabling technologies. At the same time, minimally invasive techniques for hip replacement using the direct anterior approach (DAA) have rapidly been gaining favor among surgeons. More companies are designing implant solutions to facilitate DAA, for use with and without enabling technologies. At this year’s American Association of Hip and Knee Surgeons (AAHKS) Annual Meeting, manufacturers were showcasing not one, but four new hip systems specifically designed to facilitate the direct anterior approach. Because surgeon adoption of this technique appears to be accelerating, it is potentially a significant opportunity for implant companies. In a 2022 survey of its members, AAHKS found that DAA was the most utilized for primary total hip arthroplasty THA (56%), a significant increase from 2018 when 40% of AAHKS surgeons indicated they used an anterior approach.

The introduction of these new stems almost plays out like a David vs Goliath story with two smaller US market players, NextStep Arthropedix and Corin, facing two of the four largest, Zimmer Biomet and Smith+Nephew. In this downloadable article, SmartTRAK looks at these new stems hitting the US market, including a brief history of the stems, their features and benefits, and the market positioning for each.

Recent patent applications reveal an industry focus on developing acetabular solutions

While enabling technologies in joint replacement continue to be in the spotlight, clues revealed in the shadows of data point to niche focus areas for hip implant advancements. After examining the evidence in US patent applications filed since the beginning of the year, SmartTRAK identified a trend towards acetabular implant solutions. These solutions include implant designs that can address or potentially reduce the risk of acetabular bone loss or instability, often encountered in revision hip arthroplasty.

SmartTRAK’s US Hip Replacement Market Overview points out that revision hip procedure growth remains lower than that for primary hips due to the extended implant survivorship of next-generation implants and materials. However, revision hip procedures are expected to grow with a 5-year CAGR of +3.5% to nearly 110K procedures by the end of 2028. And, according to a paper by Sahil A. Sanghavi, MS, DNB, et al., acetabular bone loss continues to be one of the most challenging issues faced by orthopedic surgeons. (J Am Acad Orthop Surg, May 2024).

At least 15 patent applications published since January 1 are related to acetabular implant solutions. The line-up of patent subjects ranges from trial implants for more accurate cup placement during surgery to custom 3D printed augments with filings from large market players to designing surgeons. In Figure 1 below, SmartTRAK outlines the most recent acetabular implant-related patent applications.

Companies riding the wave of tuck-in acquisitions.

While the chances are relatively low that the Total Joints Market will see a tsunami-size merger in 2024 that would materially change the market landscape, SmartTRAK expects to see a ripple effect from companies that continue to seek out mergers and acquisition (M&A) deals despite the challenging economic climate. Since the beginning of 2023, deals that had a more subtle effect on the market include those providing expanded international reach or initial entrance into the market. In this downloadable article, SmartTRAK highlights the acquisitions taking place since the beginning of 2023 and outlines the sentiment of some of the major companies towards future M&A. SmartTRAK also looks at what may be coming for the top Total Joints Market players, including Zimmer Biomet, Stryker, J&J/DePuy Synthes and Smith+Nephew, as they continue riding the wave of tuck-in acquisitions ...

Just click the button below to read the complete "M&A in the Total Joints Market" perspective article written by Lisa Mahan, SmartTRAK VP Product Development & IT, Sr. Analyst Total Joints.

---

SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s propriety methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK offers and how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.

SmartTRAK provides comprehensive insights into the key trends shaping the US Extremities Market, with a particular focus on upper extremities and foot & ankle sectors. Reimbursement changes, the competitive landscape of robotics and innovative advancements in fixation technologies are poised to dominate discussions, underscoring the dynamic evolution of this market segment.

 

Forces likely to influence the Total Joints Market in 2024

Final Q423 US Total Joints Market results are expected to solidify above pre-COVID growth rates for 2023. The post-pandemic patient backlog sustained strong market performance in 2023 despite tough comparisons and a challenging economic environment with rising inflation and the threat of a recession looming over healthcare consumers. What will the future hold? In this article, SmartTRAK looks at some of the trends to watch in 2024, including:

• Mixed Predictions Regarding Patient Backlog
  Several Companies including Zimmer Biomet are banking on the backlog of patients to continue boosting procedure growth through 2024. Wall Street analysts, however, are more tempered in their forward-looking projections.
• US Economic Factors Buoying Consumer Confidence
  The demand for health care is typically more resilient in the face of weaker economic conditions. However, improvements in some economic conditions in the US during 2024 are expected to buoy consumer confidence.
  
• Ongoing Shift to Outpatient Site-of-Care Despite Reimbursement Decline
  Eligible patients are continuing to choose joint replacement surgery in an outpatient or ambulatory surgery center (ASC) setting in increasing numbers. New ASCs springing up around the country are giving potential patients expanded site-of-care options.
• Ongoing Influence of ASC Economics
  ASCs facing lower reimbursement rates compared to hospital outpatient and inpatient settings will continue to look for product solutions that improve efficiency and reduce the overall cost of care.
  
• New Product Launches to Watch
  New and early-stage hip and knee product launches for both large and mid-tier Joint Replacement Market players will drive revenue growth.
  
  

Just click the button below to download and read the complete "Total Joints 2024 Trends to Watch" market outlook article and analysis by Lisa Mahan, SmartTRAK's VP Product Development & IT, Sr. Analyst TJ&E.

---

SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s propriety methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK offers and how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.

Anika’s President and CEO Cheryl Blanchard, Ph.D., discusses the Company’s expanding portfolio of shoulder preservation solutions

Anika Therapeutics entered the Reverse Shoulder Market this year with the US market release of the RevoMotion Reverse Shoulder Arthroplasty System, expanding their complement of products for shoulder joint preservation and replacement. This new offering allows the Company to compete in the rapidly growing US Market for Reverse Shoulders. Lisa Mahan, SmartTRAK Senior Analyst Total Joints & Extremities, talked with Cheryl Blanchard, PhD, President and CEO of Anika, to discuss the launch of RevoMotion, along with the X-Twist Fixation System, Integrity Patch System, Cingal next generation OA injectable and Tactoset Injectable Bone Substitute.

 

The Interview

 

SmartTRAK: RevoMotion has been out almost nine months now in limited release and you just went to full market release. Congratulations. How is that going?

Cheryl Blanchard: Thank you! Anika announced the full market release of the RevoMotion Reverse Shoulder Arthroplasty System (RSA) during the 2023 Orthopaedic Summit (OSET) Annual Meeting September 20-23 in Boston, MA and the response has been overwhelmingly positive.

We began the limited launch in January 2023 and have performed over 100 cases since then. The feedback we received and the response during the limited market release was impressive as some of the first patients in have already returned to their surgeons and asked for the same implant to be placed in their other shoulder. To have patients far enough into recovery to want the RevoMotion RSA in their other shoulder says a lot about the system and its future success. The limited release allowed us to collect feedback to better optimize the instrumentation and surgical technique for the full market release as well. Though we finished gathering feedback months ago, manufacturing instrument sets and system components takes time. That brought us right to our full market release during OSET in September.

We know that the reverse shoulder market is a crowded space. Given that probably 80% of the market is reverse shoulders, for Anika we knew we had something incredible to offer clinicians and patients based on the historic Arthrosurface design philosophies focused on bone sparing, motion preservation and anatomic design features. We also knew that with the data-backed and trusted OVOMotion with Inlay Glenoid Total Shoulder Arthroplasty System, it would be difficult to penetrate the full shoulder arthroplasty market without having a reverse option.

Additionally, there is a big shift of a lot of these products and procedures into the ASC setting. We will possibly see even more products coming into the ASC when CMS changes how they reimburse and we realized that there was a real opportunity to provide optimized instrument trays that would reduce the operating room footprint. RevoMotion has a two-tray instrumentation system that is very streamlined. The surgical technique is also very streamlined. We're hearing great feedback on it and we're excited to be in full market release coming into the fourth quarter.

That's wonderful. You mentioned the instrument trays and some of the design. If there was one thing that differentiates RevoMotion from other reverse shoulders on the market, what would you say that is?

CB:We believe and continue to hear feedback from surgeon users that having the smallest threaded glenoid base plate on the market is one of the biggest differentiators. Personally, I didn't understand the true significance of that until I started to speak directly with surgeons who had used the system. Listening to real-time feedback and observing in the OR, you realize it's a major benefit as it provides...

To download and read the complete transcript of the interview with Anika’s President & CEO Cheryl Blanchard conducted by Lisa Mahan, VP Product Development & IT, Sr. Analyst TJ&E, just click the button below.

Increased elective procedure volume recovery lifts market growth to new heights

The winds of change precipitated a strong season of growth for the Total Joints Market. Company after company reported increasing elective procedural volume recovery due to the underlying post-COVID demand. Procedure momentum and easier year-over-year comparisons drove market growth above double-digits with the US Total Joints Market growing +14.5% in Q123. Easing of staffing headwinds and normalization of surgery cancellation rates were also contributing factors to accelerating procedures.